WO2011058367A3 - Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase - Google Patents

Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase Download PDF

Info

Publication number
WO2011058367A3
WO2011058367A3 PCT/GB2010/051888 GB2010051888W WO2011058367A3 WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3 GB 2010051888 W GB2010051888 W GB 2010051888W WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3
Authority
WO
WIPO (PCT)
Prior art keywords
parp
treatment
adp
ribose
polymerase
Prior art date
Application number
PCT/GB2010/051888
Other languages
English (en)
Other versions
WO2011058367A2 (fr
Inventor
Jonathan Richard Dry
Christopher George Harbron
Darren Richard Hodgson
Alan Yin Kai Lau
Mark James O'connor
John Edward Prime
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2011058367A2 publication Critical patent/WO2011058367A2/fr
Publication of WO2011058367A3 publication Critical patent/WO2011058367A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne d'une manière générale des procédés pour traiter un cancer et des procédés de prédiction de la sensibilité d'une cellule cancéreuse à un traitement thérapeutique. En particulier, l'invention concerne les identités de gènes (biomarqueurs) qui peuvent être utilisés pour identifier des populations de personnes souffrant d'un cancer ou des individus souffrant d'un cancer qui sont susceptibles d'une réponse favorable à un traitement par un inhibiteur de poly(ADP-ribose) polymérase (PARP).
PCT/GB2010/051888 2009-11-13 2010-11-11 Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase WO2011058367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26093409P 2009-11-13 2009-11-13
US61/260,934 2009-11-13

Publications (2)

Publication Number Publication Date
WO2011058367A2 WO2011058367A2 (fr) 2011-05-19
WO2011058367A3 true WO2011058367A3 (fr) 2011-08-18

Family

ID=43500036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051888 WO2011058367A2 (fr) 2009-11-13 2010-11-11 Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase

Country Status (1)

Country Link
WO (1) WO2011058367A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807823C (fr) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methodes de prediction d'une reponse anticancereuse
CA2835339A1 (fr) * 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature pour le diagnostic d'agressivite et d'instabilite genetique d'un cancer
WO2013133876A1 (fr) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarqueurs destinés à la prédiction de la réponse à une inhibition de parp dans le cancer du sein
NZ628813A (en) * 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
WO2014138101A1 (fr) * 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Signature génique pour prédire un cancer déficient pour la recombinaison homologue (rh)
CA2912786A1 (fr) * 2013-05-21 2014-11-27 Dignity Health Signature genetique de la vulnerabilite aux inhibiteurs de la reparation par excision des bases (ber) en oncologie
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
EP3543353A1 (fr) * 2013-09-23 2019-09-25 The University of Chicago Procédés et compositions concernant une thérapie anticancéreuse au moyen d'agents endommageant l'adn
EP3137076A4 (fr) * 2014-05-02 2017-12-06 Emory University Traitements sélectifs de chimiothérapie et méthodes de diagnostic associées à ceux-ci
US10823738B2 (en) * 2015-12-07 2020-11-03 George Mason Research Foundation, Inc. Methods for breast cancer treatment
WO2018161081A1 (fr) * 2017-03-03 2018-09-07 Board Of Regents, The University Of Texas System Signatures géniques permettant de prédire la réponse à un médicament contre le cancer
CN110582490A (zh) 2017-04-10 2019-12-17 塞拉肿瘤学公司 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
WO2019063004A1 (fr) * 2017-09-30 2019-04-04 浙江数问生物技术有限公司 Application d'un indice d'efficacité de recombinaison de l'adn (rds) dans le traitement du cancer
WO2019133697A1 (fr) * 2017-12-27 2019-07-04 Tesaro, Inc. Méthodes de traitement du cancer
CN112292463A (zh) * 2018-05-15 2021-01-29 肿瘤学风险公司 用于预测癌症患者药物反应性的方法
WO2021067403A1 (fr) * 2019-10-01 2021-04-08 Immunomedics, Inc. Biomarqueurs pour une monothérapie ou une polythérapie par un conjugué anticorps-médicament
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN114934120A (zh) * 2022-06-20 2022-08-23 柳州市人民医院 一种快速鉴定早期结直肠癌的环状rna标志物的应用及诊断试剂盒
WO2024009946A1 (fr) * 2022-07-08 2024-01-11 国立大学法人東海国立大学機構 Procédé de test de l'efficacité d'un inhibiteur de parp contre le cancer de l'ovaire

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (fr) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Materiau d'emballage etanche
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPH0314319A (ja) 1989-06-13 1991-01-23 Anritsu Corp ラダー抵抗回路
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6285701B1 (en) 1998-08-06 2001-09-04 Lambda Physik Ag Laser resonator for improving narrow band emission of an excimer laser
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2352194A1 (fr) 1999-09-28 2001-04-05 Basf Aktiengesellschaft Derives d'azepinoindol, preparation et utilisation desdits derives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
WO2003007959A1 (fr) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US7157452B2 (en) 2001-12-31 2007-01-02 Mgi Gp, Inc. Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses
BR0307780A (pt) 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2004014873A1 (fr) 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. Derive de quinazoline-8-carboxyamide substitue en 4 et sel d'addition pharmaceutiquement acceptable de celui-ci
WO2004024694A1 (fr) 2002-09-10 2004-03-25 Kyorin Pharmaceutical Co., Ltd. Derive de 4-(aryle substitue)-5-hydroxyisoquinolinone
ES2376166T3 (es) 2002-11-22 2012-03-09 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal.
WO2005009398A2 (fr) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Derives de benzamide tetracyclique et leurs procedes d'utilisation
MXPA05009661A (es) 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
MXPA05012812A (es) 2003-05-28 2006-02-28 Guilford Pharm Inc Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
WO2004108723A1 (fr) 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones utilisees comme inhibiteurs de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
CN1870991A (zh) 2003-09-04 2006-11-29 安万特药物公司 作为多聚(adp－核糖)聚合酶(parp)抑制剂的被取代的吲哚类化合物
EP1687277B1 (fr) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp)
MXPA06005686A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
NZ547193A (en) 2003-12-05 2010-03-26 Janssen Pharmaceutica Nv 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
UA91007C2 (ru) 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
UA86237C2 (uk) 2004-06-30 2009-04-10 Янссен Фармацевтика Н.В. Похідні заміщеного 2-алкілхіназолінону як інгібітори parp
US7803795B2 (en) 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006024545A1 (fr) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO2006078503A2 (fr) 2005-01-07 2006-07-27 Arqule, Inc. Compositions pour moduler une parp et procedes pour la cribler
AU2006206512B2 (en) 2005-01-19 2012-09-13 Eisai Inc. Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US20070292883A1 (en) 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
WO2009121031A1 (fr) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMEIDA ET AL: "A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification", DNA REPAIR, vol. 6, no. 6, 3 May 2007 (2007-05-03), ELSEVIER, AMSTERDAM, NL, pages 695 - 711, XP022059296, ISSN: 1568-7864, DOI: 10.1016/J.DNAREP.2007.01.009 *
ANONYMUS: "PARP Inhibitors (future cancer therapy) and the importance of molecular pathology", 16 September 2009 (2009-09-16), XP002620580, Retrieved from the Internet <URL:www.innovationandchoice.com/2009/09/16/parp-inhibitors-future-cancer-therapy-and-the-importance-of-molecular-pathology> [retrieved on 20110202] *
BRUCE JAMES W ET AL: "The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment.", PLOS PATHOGENS, vol. 4, no. 11, E1000207, November 2008 (2008-11-01), pages 1 - 15, XP002620581, ISSN: 1553-7374 *
DAMIA ET AL: "Targeting DNA repair as a promising approach in cancer therapy", EUROPEAN JOURNAL OF CANCER, vol. 43, no. 12, 11 August 2007 (2007-08-11), PERGAMON PRESS, OXFORD, GB, pages 1791 - 1801, XP022196531, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.05.003 *
DRY JONATHAN R ET AL: "Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 51, 21 April 2010 (2010-04-21), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, pages 848 - 849, XP009143942, ISSN: 0197-016X *
LORD C J ET AL: "A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity", DNA REPAIR, vol. 7, no. 12, 1 December 2008 (2008-12-01), ELSEVIER, AMSTERDAM, NL, pages 2010 - 2019, XP025627852, ISSN: 1568-7864, [retrieved on 20081015], DOI: 10.1016/J.DNAREP.2008.08.014 *
MCCABE NUALA ET AL: "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition", CANCER RESEARCH, vol. 66, no. 16, 15 August 2006 (2006-08-15), AMERICAN ASSOCIATION FOR CANCER REREARCH, US, pages 8109 - 8115, XP002482543, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-0140 *
PERALTA-LEAL A ET AL: "PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases", FREE RADICAL BIOLOGY AND MEDICINE, vol. 47, no. 1, 1 July 2009 (2009-07-01), ELSEVIER SCIENCE, US, pages 13 - 26, XP026158945, ISSN: 0891-5849, [retrieved on 20090410], DOI: 10.1016/J.FREERADBIOMED.2009.04.008 *
TURNER NICHOLAS C ET AL: "A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor", EMBO JOURNAL, vol. 27, no. 9, 1 May 2008 (2008-05-01), OXFORD UNIVERSITY PRESS, SURREY, GB, pages 1368 - 1377, XP002498071, ISSN: 0261-4189, [retrieved on 20080403], DOI: 10.1038/EMBOJ.2008.61 *

Also Published As

Publication number Publication date
WO2011058367A2 (fr) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2011058367A3 (fr) Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
NZ620799A (en) Molecular diagnostic test for cancer
EP2474626A3 (fr) Détection de néoplasme à partir d&#39;un échantillon de selles
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
WO2011038155A3 (fr) Analyse génétique
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
PH12016501036A1 (en) Il-1 binding proteins
EP2518163A3 (fr) Modifications spécifiques du cancer de la prostate dans l&#39;expression du gène ERG et procédés de détection et de traitement sur la base de ces altérations
EP3296406A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
EP2481814A3 (fr) Compositions et procédés de diagnostic et de traitement des cancers
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
EP2527466A3 (fr) Variants génétiques du CHR2 utilisés comme marqueurs dans l&#39;évaluation, le diagnostic, le pronostic et le traitement d&#39;un risque de cancer du sein
WO2010024897A3 (fr) Procédés et compositions pour le traitement du cancer de la prostate ou pour l’induction d’une réponse immunitaire humorale contre le cancer de la prostate
EP2582847A4 (fr) Procédés et matériaux pour évaluer la perte d&#39;hétérozygotie
WO2010009337A3 (fr) Signatures et déterminants de la pc associés au cancer de la prostate et leurs procédés d’utilisation
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
WO2011047033A3 (fr) Biomarqueur d&#39;identification de cellules tumorales de mélanome
WO2012138783A3 (fr) Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2011088137A3 (fr) Signature de gènes impliqués dans la transduction du signal bad
WO2008128169A8 (fr) Sparc et procédés pour leur utilisation
WO2008091814A3 (fr) Évaluation de l&#39;asthme et d&#39;une expression d&#39;un gène dépendant d&#39;un allergène
WO2008011519A3 (fr) Inhibiteurs d&#39;amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2009131887A3 (fr) Procédés d’utilisation de mir-210 comme biomarqueur de l’hypoxie et comme agent thérapeutique dans le traitement du cancer
WO2009103790A3 (fr) Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques.
EP2535050A3 (fr) Compositions et procedes de detection d&#39;une maladie lysosomale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A2